Buffer for diluting cryopreserved cells

Using a HSA-based buffer with optional additives for diluting thawed cryopreserved cells addresses the contamination risk of foreign serum, enhancing cell recovery and reducing costs in regenerative medicine.

JP7582958B2Active Publication Date: 2024-11-13TERUMO KK
View PDF 7 Cites 0 Cited by

Patent Information

Application Number
JP2021551346
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-09-30
Filing Date
2020-09-30
Publication Date
2024-11-13
Estimated Expiration
2040-09-30

AI Technical Summary

Technical Problem

Existing methods for thawing cryopreserved cells in regenerative medicine often use culture media containing foreign serum, which risks contamination and are not xeno-free, leading to reduced recovery rates and increased costs due to the need for subsequent culture to achieve sufficient cell numbers.

Method used

A buffer solution containing human serum albumin (HSA) is used to dilute thawed cryopreserved cells, optionally with saccharides, amino acids, and vitamins, to maintain a xeno-free environment and enhance the recovery of viable cells, survival rate, and CD56-positive cell ratio.

Benefits of technology

This method improves the recovery of viable cells, survival rate, and CD56-positive cell ratio, reducing the need for expansion culture and lowering costs while ensuring a xeno-free environment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007582958000002
    Figure 0007582958000002
  • Figure 0007582958000001
    Figure 0007582958000001
Patent Text Reader

Abstract

The purpose of the present invention is to provide a method for recovering viable cells at a high recovery rate using a xeno-free buffer solution free from non-human heterologous components. This buffer solution contains human-derived albumin and is for diluting a cell suspension in which cryopreserved cells including somatic cells are thawed.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present disclosure relates to a method for recovering viable cells from cryopreserved cells, and a method for producing a cell culture comprising said method. [Background technology]

[0002] In recent years, attempts have been made to transplant various cells to repair damaged tissues, etc. For example, attempts have been made to use fetal cardiomyocytes, skeletal myoblasts, ES cells, etc. to repair myocardial tissue damaged by ischemic heart diseases such as angina pectoris and myocardial infarction.

[0003] As part of such attempts, cell structures formed using scaffolds and sheet-like cell cultures in which cells are formed into a sheet have been developed (see, for example, Non-Patent Documents 1 to 3).

[0004] Regarding the therapeutic applications of sheet-like cell cultures, research is underway on the use of cultured epidermal sheets to treat skin injuries such as those caused by burns, the use of corneal epithelial sheet-like cell cultures to treat corneal injuries, and the use of oral mucosa sheet-like cell cultures for endoscopic resection of esophageal cancer.

[0005] As such, with the establishment of new treatment methods based on regenerative medicine, there has been an increasing number of opportunities in recent years to freeze and preserve autologous cells, and then thaw such frozen preserved cells to recover the autologous cells and use them for treatment when forming three-dimensional structures such as artificial tissues or sheet-like cell cultures, or for direct cell transplantation.

[0006] Although cells can be preserved semi-permanently by freezing, the cells are damaged by stresses such as latent heat generated during freezing and ice crystals generated within the cells, and when retrieving the frozen cells, it is not possible to retrieve all of the frozen cells as live cells. Normally, after thawing the frozen cells, in order to secure the required amount of cells, the thawed cells must be cultured and multiplied, which requires time and cost. In addition, in the case of cell sheets created without culturing after thawing, the percentage of live cells directly affects the quality. Therefore, it is desirable to retrieve as many live cells as possible to reduce costs and improve quality. Therefore, attempts are being made to reduce physical damage to cells and increase the number of live cells by devising freezing and thawing methods.

[0007] It has been known that the decrease in recovery rate of thawed frozen cell suspensions can be suppressed by diluting them with serum-containing culture medium, such as FBS-containing culture medium, which is commonly used for cell culture. [Prior art documents] [Patent documents]

[0008] [Patent Document 1] Special Publication No. 2007-528755 [Non-patent literature]

[0009] [Non-Patent Document 1] Shimizu et al., Circ Res. 2002 Feb 22;90(3):e40-e48 [Non-Patent Document 2] Matsuura et al., Biomaterials. 2011 Oct;32(30):7355-62 [Non-Patent Document 3] Kawamura et al., Circulation. 2012 Sep 11;126(11 Suppl 1):S29-37 Summary of the Invention [Problem to be solved by the invention]

[0010] When producing clinical grafts for use in regenerative medicine, such as sheet-shaped cell cultures, it is desirable to produce them in a so-called xeno-free state, that is, in a state that does not contain any components (xenogeneic components) other than those derived from the same organism as the subject (e.g., human), but when thawing (defrosting) cryopreserved cells to produce such grafts, if a xenogeneic serum-containing culture medium, such as the FBS-containing culture medium that has been used conventionally, is used as a diluent, the cells will no longer be xeno-free, and there is a risk of contamination with allergens or pathogens. However, no diluents have been reported that maintain a xeno-free environment and allow the recovery of thawed cryopreserved cells at a recovery rate comparable to or better than conventional rates. [Means for solving the problem]

[0011] While attempting to prepare sheet-shaped cell cultures for biological transplantation using cells that are fully functional even when prepared in a xeno-free environment, the inventors discovered the new finding that using a buffer solution containing human serum albumin (HSA) instead of an FBS-containing culture medium to dilute a cell suspension obtained by thawing cryopreserved cells enables more efficient recovery of live cells than when an FBS-containing culture medium is used. Based on this finding, the inventors conducted further research and completed the present invention.

[0012] That is, the present invention relates to the following: <1> A buffer solution containing human albumin for diluting cell suspensions obtained by thawing cryopreserved cells, including somatic cells. <2> The human-derived albumin is human serum albumin; <1> Buffer solution according to claim 1. <3> The concentration of human albumin is 1.0% or more. <1> or <2> Buffer solution according to claim 1. <4> The buffer solution comprises sugars, amino acids and vitamins. <1> ~ <3> 13. The buffer solution according to claim 12, <5> A buffer solution is added dropwise to the cell suspension at a constant rate to dilute the cell suspension. <1> ~ <4> 13. The buffer solution according to claim 12, <6> <1> ~ <5> A kit comprising any one of the human albumin-containing buffer solutions described above.

[0013] <7> A method for recovering viable cells from cryopreserved cells including somatic cells, the method comprising a step of diluting a cell suspension obtained by thawing the cryopreserved cells with a buffer containing human albumin. <8> A method for increasing one or more ratios selected from the group consisting of the number of recovered viable cells, survival rate, and recovery rate of cryopreserved cells including somatic cells, the method comprising a step of diluting a cell suspension obtained by thawing the cryopreserved cells with a buffer containing human albumin. <9> Somatic cells are skeletal myoblasts, and the ratio of CD56-positive cells is increased <7> or <8> The method described above. <10> The diluting step comprises dripping the buffer solution into the cell suspension at a constant rate. <7> ~ <9> 2. The method according to claim 1 , <11> The buffer solution contains sugars, amino acids and vitamins. <7> ~ <10> 2. The method according to claim 1 , <12> <7> ~ <11> 2. A method for producing a graft, comprising the method according to any one of the preceding claims. <13> <12> A graft produced by the method described in. <14> <12> 2. A method of treating a cardiac disease in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a graft produced by the method described in claim 1. <15> A method for increasing one or more ratios selected from the group consisting of the number of recovered viable cells, the survival rate, and the recovery rate of cryopreserved cells including somatic cells, the method comprising the steps of adding one or more components selected from the group consisting of sugars, vitamins, and amino acids to a buffer solution containing human-derived albumin, and thawing the cryopreserved cells with the added buffer solution to obtain a cell suspension, and diluting the cell suspension with the buffer solution containing human-derived albumin. <16> Somatic cells are skeletal myoblasts, and the ratio of CD56-positive cells is increased <15> The method described above. <17> The diluting step comprises dripping the buffer solution into the cell suspension at a constant rate. <15> or <16> The method described above. Effect of the Invention

[0014] The present invention improves the number of viable cells that can be recovered in a xeno-free environment by diluting a cell suspension obtained by thawing cryopreserved cells with a buffer solution containing human albumin instead of a culture solution containing FBS, which is a xenogeneic component. The present invention allows high numbers of viable cells to be recovered, survival rates, recovery rates, and / or ratios of CD56-positive cells even after freezing and thawing, making it possible to ensure a sufficient number of viable cells, especially when the cells are used without proliferation culture after thawing. This not only reduces the cost and labor of cell culture after thawing, but also expands the options for cell sheets that can be applied to regenerative medicine. [Brief description of the drawings]

[0015] [Figure 1] FIG. 1 shows the recovered viable cell ratio when diluted with DMEM containing HSA at various concentrations, assuming the recovered viable cell ratio when diluted with DMEM containing no HSA to be 1. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0016] The present invention will be described in detail below. Unless otherwise defined herein, all technical and scientific terms used herein have the same meaning as those commonly understood by those skilled in the art. All patents, applications and other publications and information referenced herein are incorporated herein by reference in their entirety. In addition, in the event of any discrepancy between the publications referenced herein and the description of this specification, the description of this specification shall prevail.

[0017] (1) Human albumin-containing buffer solution The present disclosure includes a buffer containing human albumin for diluting a cell suspension obtained by thawing cryopreserved cells.

[0018] In the present disclosure, "cryopreserved cells" usually refers to the cryopreserved cells themselves, but may also refer to a cryopreservation unit of cryopreserved cells. In this case, a cryopreservation unit refers to a group of cells that are cryopreserved together as a group, for example, in a single tube. Thus, in this case, when the "cryopreserved cells" are thawed, a "cell suspension" that was frozen is obtained.

[0019] The buffer solution of the present invention relates to a buffer solution for diluting a cell suspension obtained by thawing frozen preserved cells, and is characterized by containing human serum albumin. Usually, when thawing frozen preserved cells to recover live cells, the thawed cell suspension is diluted by adding an FBS-containing culture medium to the cell suspension for the purpose of reducing the effect of cytotoxic components such as DMSO present in the thawed cell suspension. The present inventors have found that diluting with a buffer solution containing human serum albumin (HSA) instead of an FBS-containing culture medium in the dilution step can achieve xeno-free cells while achieving high recoverable viable cell count, survival rate, recovery rate and / or CD56 positive cell rate.

[0020] The buffer solution that can be used in the present invention is not particularly limited, but from the viewpoint of increasing the high recovery rate of cells, it is preferable that it does not cause physicochemical damage to cells. For example, it is preferable that it contains one or more components selected from the group consisting of inorganic salts, sugars, amino acids, and vitamins, and it is particularly preferable that it contains all of inorganic salts, sugars, amino acids, and vitamins. Examples of buffer solutions include, but are not limited to, known buffer solutions such as Hanks' balanced salt solution and phosphate buffered saline, as well as basal liquid media such as DMEM, MEM, F12, DMEM / F12, DME, RPMI1640, MCDB (MCDB102, 104, 107, 120, 131, 153, 199, etc.), L15, SkBM, and RITC80-7. Many of these basal media are commercially available, and their compositions are also publicly known. However, when used in the production method of the present invention, the composition may be appropriately changed depending on the cell type and cell conditions, and one or more components selected from the group consisting of sugars, amino acids, and vitamins may be appropriately added to a known buffer solution.

[0021] The saccharide to be added is not limited as long as it is a saccharide that is commonly used in cell culture, and any monosaccharide or polysaccharide, such as glucose, galactose, fructose, mannose, lactose, sucrose, etc., can be used. In the present invention, the saccharide also includes pyruvic acid and lactic acid that are generated by decomposing glucose in the glycolysis system. The preferred saccharide to be added is glucose.

[0022] The vitamins to be added are not limited as long as they are vitamins commonly used in cell culture, and examples thereof include thiamine, choline, riboflavin, niacin, pantothenic acid, pyridoxal, biotin, folic acid, cyanocobalamin, ascorbic acid, niacinamide, vitamin A, vitamin D, vitamin E, vitamin K, i-inositol, D-pantothenic acid, pyridoxal, riboflavin, thiamine, ascorbic acid, and analogs, salts, and / or hydrates thereof.

[0023] The amino acid is not limited as long as it is a sugar commonly used in cell culture, and L- or D-alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, or salts and / or hydrates thereof can be used, with L-arginine HCl, L-cystine 2HCl, L-glutamine, glycine, L-histidine, L-isoleucine, L-leucine, L-lysine, L-methionine, L-phenylalanine, L-serine, L-threonine, L-tryptophan, L-tyrosine, L-valine, and the like being preferred. In addition, any component commonly used in cell culture may be included, such as pyruvic acid, hypoxanthine, linoleic acid, α-lipoic acid, putrescine, thymidine, etc.

[0024] The sugars, vitamins, and amino acids are not limited as long as they are at concentrations that do not damage cells. For example, sugars may be 0.001 to 0.01%, vitamins may be 0.00001 to 0.0001% in total, and amino acids may be 0.0005% to 0.005% in total.

[0025] The human-derived albumin used in the present invention is not particularly limited, and may be, for example, human serum albumin, human milk albumin, or human muscle albumin, preferably human serum albumin. Here, human-derived albumin includes albumin derived from living organisms such as blood and breast milk, as well as albumin produced by genetic recombination using a gene encoding human-derived albumin.

[0026] In the present invention, the buffer solution containing human-derived albumin is, for example, 0.5% by weight or more, 1% by weight or more, 1.25% by weight or more, 2.5% by weight or more, 3% by weight or more, 5% by weight or more, 10% by weight or more, 15% by weight or more, 20% by weight or more, 25% by weight or more, 30% by weight or more, 35% by weight or more, 40% by weight or more, 45% by weight or more, 50% by weight or more, preferably 1.0% or more, more preferably 1.25% or more, more preferably 2.0% or more, particularly preferably 2.5% or more. The buffer solution containing human-derived albumin is, for example, 60% by weight or less, 50% by weight or less, 45% by weight or less, 40% by weight or less, 35% by weight or less, 30% by weight or less, 25% by weight or less, 20% by weight or less, 15% by weight or less, 10% by weight or less, 5% by weight or less, 3% by weight or less, 1% by weight or less, 0.5% by weight or less. Therefore, the range of the human-derived albumin content may be any combination of these upper and lower limits, and includes, but is not limited to, ranges such as 0.5 to 60% by weight, 1 to 20% by weight, 1.25 to 15% by weight, and 2.5 to 20% by weight.

[0027] (2) Method for recovering viable cells from cryopreserved cells The method of the present invention further relates to a method for recovering viable cells from cryopreserved cells, which comprises diluting a cell suspension obtained by thawing the cryopreserved cells with a buffer containing human albumin. The method of this embodiment will be described below step by step. <Thawing of frozen stored cells> In this step, the cryopreserved cells may be thawed under any conditions known in the art. Generally, slow thawing can cause physical damage to the cells due to ice crystals, so the cells are usually thawed by quickly warming the cells using a water bath set at about 37°C. In this step, any method known in the art to improve the recovery of live cells can be used.

[0028] In the present invention, the cells are not particularly limited as long as they can be cryopreserved, and any cells known in the art can be used. The term "live cells" refers to living cells or cell populations, cell mixtures, structures, tissues, etc. that contain the cells. In a preferred embodiment, the live cells are cells that have not been genetically introduced. The live cells are not particularly limited as long as they can form grafts such as sheet-shaped cell cultures, and are, for example, somatic cells. The live cells are preferably adhesive cells (adherent cells). The adhesive cells include, for example, adhesive somatic cells (e.g., cardiomyocytes, fibroblasts, epithelial cells, endothelial cells, hepatocytes, pancreatic cells, kidney cells, adrenal cells, periodontal ligament cells, gingival cells, periosteal cells, skin cells, synovial cells, chondrocytes, etc.) and stem cells (e.g., myoblasts, muscle satellite cells, tissue stem cells such as cardiac stem cells, mesenchymal stem cells, etc.). The somatic cells may be stem cells, particularly those differentiated from iPS cells (iPS cell-derived adhesive cells). Non-limiting examples of cells that may make up the sheet-shaped cell culture include myoblasts, muscle satellite cells, cardiac muscle cells, fibroblasts, epithelial cells, endothelial cells, hepatic cells, pancreatic cells, kidney cells, adrenal cells, periodontal ligament cells, gingival cells, periosteal cells, skin cells, synovial cells, and chondrocytes, with CD56-positive cells such as myoblasts and / or muscle satellite cells being preferred.

[0029] In the present disclosure, "myoblasts" are precursor cells of striated muscle cells, and include skeletal myoblasts and cardiac myoblasts. In the present disclosure, "skeletal myoblasts" refers to myoblasts present in skeletal muscle. Skeletal myoblasts are well known in the art and can be prepared from skeletal muscle by any known method (e.g., the method described in JP 2007-89442 A) or can be obtained commercially (e.g., Lonza, Cat# CC-2580). Skeletal myoblasts can be identified by markers such as, but not limited to, CD56, α7 integrin, myosin heavy chain IIa, myosin heavy chain IIb, myosin heavy chain IId (IIx), MyoD, Myf5, Myf6, myogenin, desmin, and PAX3. In the present disclosure, "muscle satellite cells" are precursor cells of skeletal myoblasts and can be identified by markers such as, but not limited to, CD56, CD34, Myogenin, Myf5, Pax7, etc. In certain embodiments, the skeletal myoblasts are CD56 positive. The skeletal myoblasts and / or muscle satellite cells may be derived from any organism with skeletal muscle, including, but not limited to, mammals such as, but not limited to, humans, non-human primates, rodents (such as mice, rats, hamsters, guinea pigs), rabbits, dogs, cats, pigs, horses, cows, goats, sheep, etc. In one embodiment, the skeletal myoblasts and / or muscle satellite cells are mammalian skeletal myoblasts and / or muscle satellite cells. In certain embodiments, the skeletal myoblasts and / or muscle satellite cells are human skeletal myoblasts and / or human muscle satellite cells.

[0030] The amount of cells to be cryopreserved may vary depending on the volume of the container in which they are cryopreserved, but typically a cell suspension for cryopreservation is 1 × 10 5 ~5×10 7 The cell density is adjusted to about 1 / ml and dispensed into a container for freezing cells. Ideally, all the frozen cells are recovered as viable cells, so the number of cells in the cell suspension before cryopreservation can be used as a parameter when calculating the number of viable cells to be recovered.

[0031] As the cryopreservation solution, any solution known in the art to be used for cryopreservation of cells can be used, and is available from many manufacturers. In addition, a normal cell culture medium may be used, or a medium containing a cryoprotectant such as dimethyl sulfoxide (DMSO) or glycerol, usually at about 1 to 20%, preferably at about 5 to 10%, may be used. Furthermore, 100% human serum may be used instead of the medium. The container for frozen cells may be any container commonly used in the art, such as a commercially available cryovial, ampule, or cryopreservation bag.

[0032] <Dilution of cell suspension> As described above, the cell suspension obtained by thawing may contain cytotoxic components (e.g., DMSO, etc.), and the effects of the cytotoxic components can be reduced by diluting the cell suspension. The method of the present invention is characterized in that a buffer containing human-derived albumin is used during the dilution to increase one or more selected from the group consisting of the number of viable cells recovered from the thawed cells, the survival rate, the recovery rate, and / or the ratio of CD56-positive cells. The buffer and the type and concentration of albumin that can be used for dilution are as detailed above for the buffer containing human-derived albumin.

[0033] In this step, the method of dilution is not particularly limited, but it is preferable to suppress the osmotic pressure load when adding the buffer solution, and for example, the buffer solution can be added to the cell suspension at a constant dripping rate. The dripping at a constant rate may be performed by one or more dripping steps having a constant dripping rate. The dilution may be performed while the thawed cell suspension is still in the cryopreservation container, or may be performed after transferring to another container. When transferring to another container, in order to increase the survival rate of the thawed cells, the cryopreservation container after transferring the cell suspension is washed with a buffer containing human albumin, and this washing solution is added to the cell suspension. The addition of such a washing solution also corresponds to dilution in the present invention. Therefore, in one embodiment of the present invention, the buffer includes a washing solution used to wash the cryopreservation container after transferring the thawed cell suspension to another container, and a freshly prepared buffer that has not been used to wash the cryopreservation container.

[0034] The dilution of cells can be carried out by any known method, including, but not limited to, diluting the cells by suspending them in a buffer solution, centrifuging them, discarding the supernatant, and recovering the precipitated cells. Typically, the dilution of cells is carried out immediately after thawing the frozen cells, and in the step of diluting the cells, the cycle of suspension, centrifugation, and recovery may be carried out once or multiple times (e.g., 2, 3, 4, 5 times, etc.).

[0035] The recovery method of the present invention may include a step of washing the cells after thawing the cryopreserved cells, diluting them with an albumin-containing buffer solution, and recovering them, and before the step of forming a sheet-shaped cell culture. The washing of the cells may be performed by any known method, and typically, for example, is achieved by suspending the cells in a washing solution (such as a culture solution (e.g., medium, etc.) or a physiological buffer solution (e.g., PBS, HBSS, etc.) containing or not containing human serum albumin, centrifuging the cells, discarding the supernatant, and recovering the precipitated cells, but is not limited thereto. In the step of washing the cells, such a cycle of suspension, centrifugation, and recovery may be performed once or multiple times (e.g., 2, 3, 4, 5 times, etc.). In one embodiment of the present invention, the step of washing the cells is performed immediately after the step of diluting the cells.

[0036] (3) A method for increasing the number of recovered viable cells, the survival rate, the recovery rate, and / or the proportion of CD56-positive cells The present disclosure further includes a method for increasing one or more ratios selected from the group consisting of the number of recovered viable cells, the survival rate, and the recovery rate of cryopreserved cells, the method comprising a step of diluting a cell suspension obtained by thawing cryopreserved cells with a buffer containing human albumin. In one aspect of the present invention, when the cells include skeletal myoblasts and / or muscle satellite cells, the step of diluting the thawed cell suspension with a buffer containing human albumin can increase one or more selected from the group consisting of the number of recovered viable cells, the survival rate, the recovery rate, and the ratio of CD56-positive cells. The present inventors have found that by adding sugars, vitamins and / or amino acids to the components contained in the human-derived albumin-containing buffer solution used in the method of the present invention, it is possible to increase one or more selected from the group consisting of the number of recovered viable cells, survival rate, recovery rate, and the ratio of CD56-positive cells. The present invention includes a method for increasing one or more selected from the group consisting of the number of recovered viable cells, survival rate, recovery rate and / or ratio of CD56 positive cells of cryopreserved cells, the method comprising the steps of adding one or more components selected from the group consisting of sugars, vitamins and amino acids to a buffer solution containing human albumin, and diluting a cell suspension obtained by thawing the cryopreserved cells with the added buffer solution.

[0037] In one embodiment of the present invention, any or all of the sugars, amino acids, and vitamins not contained in the human-derived albumin-containing buffer can be added to a human-derived albumin-containing buffer that does not contain any or all of the sugars, vitamins, and amino acids. Preferably, all of the sugars, amino acids, and vitamins are included. For example, when Hanks' balanced salt solution containing human-derived albumin is used as a dilution buffer, the number of recovered live cells, the survival rate, the recovery rate, and / or the ratio of CD56-positive cells can be increased by adding amino acids and vitamins to the dilution buffer and using it to dilute a cell suspension obtained by thawing frozen preserved cells. The sugars, vitamins, and / or amino acids may be added at any timing as long as they are added when the cells are diluted. Therefore, they may be added to the human-derived albumin buffer before dilution, or they may be dissolved in another solution and added to the cell suspension diluted with the human-derived albumin buffer.

[0038] (4) Method for producing sheet-shaped cell culture and kit As described above, the cells collected by the collection method of the present invention can be particularly preferably used without subsequent expansion culture. Therefore, in one aspect, the present invention relates to a method for producing a graft using the cells collected by the collection method of the present invention.

[0039] In the present invention, the term "graft" refers to a structure for transplantation into a living body, and particularly refers to a transplantation structure containing cells as a component. In a preferred embodiment, the graft is a transplantation structure that does not contain any structure (e.g., a scaffold, etc.) other than cells and cell-derived substances. Examples of the graft in the present disclosure include, but are not limited to, sheet-shaped cell cultures, spheroids, cell aggregates, etc., and are preferably sheet-shaped cell cultures or spheroids, and more preferably sheet-shaped cell cultures.

[0040] In the present disclosure, the term "sheet-shaped cell culture" refers to a sheet-shaped product in which cells are connected to each other. The cells may be connected to each other directly (including via cellular elements such as adhesion molecules) and / or via an intervening substance. The intervening substance is not particularly limited as long as it is a substance that can at least physically (mechanically) connect the cells to each other, and examples thereof include extracellular matrices. The intervening substance is preferably derived from cells, particularly from the cells that constitute the sheet-shaped cell culture. The cells are at least physically (mechanically) connected, but may also be functionally connected, for example, chemically or electrically. The sheet-shaped cell culture may be one composed of one cell layer (single layer) or one composed of two or more cell layers (laminated (multilayer), for example, two layers, three layers, four layers, five layers, six layers, etc.). The sheet-shaped cell culture may have a three-dimensional structure with a thickness exceeding that of a single cell, without the cells showing a clear layer structure. For example, in a vertical cross section of a sheet-shaped cell culture, the cells may not be uniformly aligned in the horizontal direction but may be arranged unevenly (eg, in a mosaic pattern).

[0041] The graft of the present disclosure, particularly the sheet-shaped cell culture, preferably does not include a scaffold (support). A scaffold may be used in the art to attach cells to its surface and / or inside and maintain the physical integrity of the graft, such as a sheet-shaped cell culture. For example, a membrane made of polyvinylidene difluoride (PVDF) is known, but the graft of the present disclosure can maintain its physical integrity without such a scaffold. In addition, the graft of the present disclosure preferably consists only of substances derived from the cells that constitute the graft, and does not include other substances.

[0042] The culture substrate is not particularly limited as long as the cells can form a cell culture thereon, and includes, for example, containers of various materials and / or shapes, solid or semi-solid surfaces in the container, and the like. The container is preferably made of a structure or material that is impermeable to liquids such as culture fluid. Examples of such materials include, but are not limited to, polyethylene, polypropylene, Teflon (registered trademark), polyethylene terephthalate, polymethyl methacrylate, nylon 6,6, polyvinyl alcohol, cellulose, silicon, polystyrene, glass, polyacrylamide, polydimethylacrylamide, metals (e.g., iron, stainless steel, aluminum, copper, brass), and the like. In addition, the container preferably has at least one flat surface. Examples of such containers include, but are not limited to, a culture vessel having a bottom surface made of a culture substrate on which a cell culture can be formed, and liquid-impermeable sides. Specific examples of such culture vessels include, but are not limited to, cell culture dishes, cell culture bottles, and the like. The bottom surface of the vessel may be transparent or opaque. If the bottom surface of the vessel is transparent, cells can be observed, counted, and the like from the back side of the vessel. The container may have a solid or semi-solid surface inside. Examples of solid surfaces include plates and containers made of the various materials described above, and examples of semi-solid surfaces include gels, soft polymer matrices, etc. The culture substrate may be made of the above materials, or a commercially available product may be used.

[0043] Preferred culture substrates include, but are not limited to, substrates having an adhesive surface suitable for forming a sheet-shaped cell culture, substrates having a low adhesive surface suitable for forming spheroids, and / or substrates having a uniform well-like structure. Specifically, in the case of forming a sheet-shaped cell culture, substrates having a surface coated with a hydrophilic compound such as corona discharge-treated polystyrene, collagen gel, or hydrophilic polymer, and substrates having a surface coated with extracellular matrices such as collagen, fibronectin, laminin, vitronectin, proteoglycan, or glycosaminoglycan, or cell adhesion factors such as cadherin family, selectin family, or integrin family are included. In addition, such substrates are commercially available (e.g., Corning(R) TC-Treated Culture Dish, Corning, etc.). In the case of spheroid formation, examples of suitable substrates include soft agar, a temperature-responsive gel (trade name: Mebiol Gel) in which poly(N-isopropylacrylamide) (PIPAAm) is crosslinked with polyethylene glycol (PEG), a substrate coated with a non-cell adhesive compound such as hydrogels such as polyhydroxyethyl methacrylate (polyHEMA) and 2-methacryloyloxyethyl phosphorylcholine (MPC) polymer, and / or a substrate having a uniform uneven surface structure. Such substrates are also commercially available (e.g., EZSPHERE(R)). The culture substrate may be entirely or partially transparent or opaque.

[0044] The surface of the culture substrate may be coated with a material whose physical properties change in response to a stimulus, such as temperature or light. Examples of such materials include, but are not limited to, (meth)acrylamide compounds, N-alkyl-substituted (meth)acrylamide derivatives (e.g., N-ethylacrylamide, Nn-propylacrylamide, Nn-propylmethacrylamide, N-isopropylacrylamide, N-isopropylmethacrylamide, N-cyclopropylacrylamide, N-cyclopropylmethacrylamide, N-ethoxyethylacrylamide, N-ethoxyethylmethacrylamide, N-tetrahydrofurfurylacrylamide, N-tetrahydrofurfurylmethacrylamide, etc.), N,N-dialkyl-substituted (meth)acrylamide derivatives (e.g., N,N-dimethyl(meth)acrylamide, N,N-ethylmethylacrylamide, N,N-diethylacrylamide, etc.), (meth)acrylamide derivatives having a cyclic group (e.g., 1-(1- Known materials such as temperature-responsive materials made of homopolymers or copolymers of 1-(1-oxo-2-propenyl)-pyrrolidine, 1-(1-oxo-2-propenyl)-piperidine, 4-(1-oxo-2-propenyl)-morpholine, 1-(1-oxo-2-methyl-2-propenyl)-pyrrolidine, 1-(1-oxo-2-methyl-2-propenyl)-piperidine, 4-(1-oxo-2-methyl-2-propenyl)-morpholine, or vinyl ether derivatives (e.g., methyl vinyl ether), light-absorbing polymers having an azobenzene group, copolymers of vinyl derivatives of triphenylmethane leucohydroxide and acrylamide monomers, and light-responsive materials such as N-isopropylacrylamide gel containing spirobenzopyran can be used (e.g., see JP-A-2-211865 and JP-A-2003-33177). By applying a certain stimulus to these materials, their physical properties, such as hydrophilicity or hydrophobicity, can be changed, and the detachment of cell cultures attached to the materials can be promoted. Culture dishes coated with temperature-responsive materials are commercially available (e.g., UpCell® by CellSeed Inc.), and these can be used in the manufacturing method of the present disclosure.

[0045] The culture substrate may have various shapes. The area is not particularly limited, but may be, for example, about 1 cm to about 200 cm. 2 , about 2 cm 2 ~about 100cm 2 , about 3cm 2 ~about 50cm 2 For example, the culture substrate may be a circular culture dish with a diameter of 10 cm. In this case, the area is 56.7 cm 2 The culture surface may be flat or may have an uneven structure. When the culture surface has an uneven structure, it is preferable that the uneven structure is uniform.

[0046] In the present disclosure, "pluripotent stem cells" is a term well known in the art and refers to cells that have the ability to differentiate into all lineages of cells belonging to the three germ layers, i.e., endoderm, mesoderm, and ectoderm. Non-limiting examples of pluripotent stem cells include embryonic stem cells (ES cells), nuclear transfer embryonic stem cells (ntES cells), and induced pluripotent stem cells (iPS cells). Induced pluripotent stem cells (iPS cells) are cells induced by introducing genes. In general, when inducing differentiation of pluripotent stem cells into specific cells, the pluripotent stem cells are first cultured in suspension to form aggregates of cells of any of the above three germ layers, and then the cells forming the aggregates are induced to differentiate into the specific cells of interest.

[0047] In the present disclosure, "differentiation-induced cells derived from pluripotent stem cells" refers to any cells that have been subjected to differentiation-induced treatment so as to differentiate from pluripotent stem cells into a specific type of cell. Non-limiting examples of differentiation-induced cells include muscle cells such as skeletal myoblasts, muscle satellite cells, and cardiomyocytes, nervous system cells such as neuron cells, oligodendrocytes, and dopamine-producing cells, retinal cells such as retinal pigment epithelial cells, hematopoietic cells such as blood cells and bone marrow cells, immune-related cells such as T cells, NK cells, NKT cells, dendritic cells, and B cells, organ-constituting cells such as hepatic cells, pancreatic β cells, and kidney cells, chondrocytes, germ cells, and other cells, as well as precursor cells and somatic stem cells that differentiate into these cells. Typical examples of such precursor cells and somatic stem cells include, for example, mesenchymal stem cells in cardiomyocytes, multipotent cardiac progenitor cells, unipotent cardiac progenitor cells, neural stem cells in nervous system cells, and hematopoietic stem cells and lymphoid stem cells in hematopoietic cells and immune-related cells. Differentiation induction of pluripotent stem cells can be performed using any known method. For example, differentiation induction from pluripotent stem cells to cardiomyocytes can be performed based on the techniques described in Miki et al., Cell Stem Cell 16, 699-711, June 4, 2015 and WO2014 / 185358. When differentiation-induced cells derived from pluripotent stem cells such as iPS-derived cardiomyocytes are used as the desired cells, a process for removing undifferentiated cells may be performed after differentiation induction. The process for removing undifferentiated cells is known in the art, and for example, the methods described in WO2017 / 038562, WO2016 / 072519, and WO2007 / 088874 can be used.

[0048] The differentiation-induced cells may be cells induced from iPS cells into which any useful gene other than the gene for reprogramming has been introduced. Non-limiting examples of such cells include T cells induced from iPS cells into which the gene for the chimeric antigen receptor described in Themeli M. et al. Nature Biotechnology, vol. 31, no. 10, pp. 928-933, 2013 has been introduced. In addition, cells into which any useful gene has been introduced after differentiation from pluripotent stem cells are also included in the differentiation-induced cells of the present invention.

[0049] To form a higher density graft, particularly a sheet-shaped cell culture, the culture substrate may be coated with blood-derived components and / or cell adhesive components. "Coated with blood-derived components and / or cell adhesive components" means a state in which blood-derived components such as serum and / or cell adhesive components are attached to the surface of the culture substrate, and such a state can be obtained, for example, by treating the culture substrate with blood-derived components and / or cell adhesive components, without being limited thereto. Treatment with blood-derived components and / or cell adhesive components includes, for example, contacting the culture substrate with serum and / or cell adhesive components and, if necessary, incubating for a predetermined period of time. The serum and / or cell adhesive components used for coating may be serum of the same species as the origin of the seeded cells (allogeneic serum) or serum of a different species (xenogeneic serum), such as FBS, but is preferably allogeneic serum, and more preferably serum obtained from the individual from which the seeded cells are derived (autologous serum). Other blood-derived components include albumin and platelet lysate. Examples of cell adhesive components used for coating include extracellular matrices such as collagen, fibronectin, laminin, vitronectin, proteoglycan, and glycosaminoglycan, as well as the cadherin family, the selectin family, and the integrin family.

[0050] The seeding of cells onto the culture substrate can be carried out by any known method and condition. The seeding of cells onto the culture substrate can be carried out, for example, by injecting a cell suspension in which cells are suspended in a culture medium into the culture substrate (culture vessel). For the injection of the cell suspension, a tool suitable for injecting a cell suspension, such as a dropper or pipette, can be used. The seeding density of cells is a density at which a sheet-shaped cell culture can be formed, and this density may vary depending on the desired cells, but a person skilled in the art can select an appropriate density from methods known in the art. For example, in the case of a sheet-shaped cell culture containing skeletal myoblasts, the seeding density can be, for example, 2.0×10 5 pieces / cm 2 or more, but may be sown at higher densities.

[0051] Examples of higher densities include a density at which confluence is reached, i.e., a density at which the cells are expected to cover the entire adhesive surface of the culture vessel when seeded, a density at which the cells are expected to come into contact with each other when seeded, a density at which contact inhibition occurs, or a density at which cell growth is substantially stopped due to contact inhibition, or higher. There is no particular upper limit for the seeding density, but if the density is too high, many cells will die, resulting in inefficiency. In one embodiment of the present disclosure, the seeding density is, for example, about 1.0×10 6 pieces / cm 2 ~Approx. 1.0×10 7 pieces / cm 2 , about 1.0×10 6 pieces / cm 2 ~Approx. 5.0×10 6 pieces / cm 2 , about 1.0×10 6 pieces / cm 2 ~Approx. 3.0×10 6 pieces / cm 2 , about 1.5×10 6 pieces / cm 2 ~Approx. 1.0×10 7 pieces / cm 2 , about 1.5×10 6 pieces / cm 2 ~Approx. 5.0×10 6 pieces / cm 2 , about 1.5×10 6pieces / cm 2 ~Approx. 3.0×10 6 pieces / cm 2 , about 2.0×10 6 pieces / cm 2 ~Approx. 1.0×10 7 pieces / cm 2 , about 2.0×10 6 pieces / cm 2 ~Approx. 5.0×10 6 pieces / cm 2 , about 2.0×10 6 pieces / cm 2 ~Approx. 3.0×10 6 pieces / cm 2 In a preferred embodiment, the seeding density is about 1.76×10 6 pieces / cm 2 ~Approx. 2.33×10 6 pieces / cm 2 It is.

[0052] The cell population to be seeded may contain other cells as long as it contains the desired cells (e.g., skeletal myoblasts or muscle satellite cells), and when the desired cells are skeletal myoblasts, it may further contain, for example, fibroblasts or mesenchymal stem cells. The cell population may be a cell population collected from tissue (e.g., skeletal muscle tissue) as it is, or a cell population obtained by inducing differentiation from iPS cells using, for example, the techniques described in Miki et al., Cell Stem Cell 16, 699-711, June 4, 2015 or WO2014 / 185358, or may be used as it is, or may be used after cryopreservation, pre-culture, removal of undifferentiated cells, or the like. In a preferred embodiment, the cell population to be seeded is a cell population that has been induced to differentiate from iPS cells, seeded on a culture substrate (preferably on a planar culture substrate), subjected to adhesion culture, and then recovered. Cryopreservation and thawing may be performed before or after such adhesion culture. By carrying out adhesion culture, it becomes possible to achieve a high probability of forming a high quality graft in the subsequent graft formation. In such an adhesion culture step, the culture conditions may be similar to those for normal adhesion culture. For example, the culture may be performed under conditions of 37°C and 5% CO2 using a commercially available culture vessel for adhesion culture. The seeding density of the cells may be any density that does not prevent the formation of adhesion between cells and / or between the cells and the culture substrate, and may be, for example, a subconfluent density, or a density that reaches confluence or higher. The culture time may be a time that allows the formation of adhesion between cells and / or between the cells and the culture substrate, and specifically may be, for example, about 2 to 24 hours, 2 to 12 hours, 2 to 6 hours, or 2 to 4 hours.

[0053] The culture medium used in the production method of the present invention is not particularly limited as long as it can maintain cell survival, but typically, a medium containing amino acids, vitamins, and electrolytes as main components can be used. In one embodiment of the present invention, the culture medium is based on a basal medium for cell culture. Such basal media include, but are not limited to, DMEM, MEM, F12, DMEM / F12, DME, RPMI1640, MCDB (MCDB102, 104, 107, 120, 131, 153, 199, etc.), L15, SkBM, RITC80-7, etc. Many of these basal media are commercially available, and their compositions are also publicly known. However, when used in the production method of the present invention, the composition may be appropriately changed depending on the cell type and cell conditions.

[0054] In another aspect, the present invention relates to a kit for producing the above-mentioned graft, in particular a sheet-shaped cell culture, comprising some or all of the components used in the production of a sheet-shaped cell culture without undergoing proliferation culture. The kit of the present invention may include, but is not limited to, a human albumin-containing buffer solution for diluting the cryopreserved cells after thawing, as well as cells that will form the graft (e.g., cryopreserved cells, cells recovered by the recovery method of the present invention, etc.), culture medium, culture dishes, equipment (e.g., pipettes, droppers, tweezers, etc.), instructions for producing the sheet-like cell culture (e.g., instructions for use, media recording information regarding the production method and the recovery method of the cryopreserved cells of the present invention, such as a flexible disk, CD, DVD, Blu-ray disk, memory card, USB memory, etc.), and the like.

[0055] (5) Treatment method using a graft Another aspect of the present disclosure relates to a method for treating a disease using a graft, particularly a sheet-shaped cell culture, produced by the production method of the present disclosure. In one embodiment of the present invention, the sheet-shaped cell culture produced by the production method of the present disclosure contains skeletal myoblasts and / or satellite cells. In another embodiment of the present invention, the sheet-shaped cell culture produced by the production method of the present disclosure contains skeletal myoblasts, satellite cells, fibroblasts and / or mesenchymal stem cells. The sheet-shaped cell culture of the present disclosure is useful for treating diseases that are improved by the application of the sheet-shaped cell culture, for example, various diseases associated with tissue abnormalities. Thus, in one embodiment, the sheet-shaped cell culture of the present disclosure is intended for use in treating diseases that are improved by the application of the sheet-shaped cell culture, particularly diseases associated with tissue abnormalities. The sheet-shaped cell culture of the present disclosure has similar inherent properties of the constituent cells, except for having a higher mechanical strength than the conventional sheet-shaped cell culture, and can therefore be applied to tissues and diseases that can be treated by the conventional sheet-shaped cell culture containing at least myoblasts or fibroblasts. Tissues to be treated include, but are not limited to, cardiac muscle, cornea, retina, esophagus, skin, joints, cartilage, liver, pancreas, gums, kidney, thyroid, skeletal muscle, middle ear, bone marrow, stomach, small intestine, duodenum, large intestine, and other digestive tracts.In addition, diseases to be treated include, but are not limited to, heart diseases (e.g., myocardial injury (myocardial infarction, cardiac trauma), cardiomyopathy, etc.), corneal diseases (e.g., corneal epithelial stem cell exhaustion syndrome, corneal damage (thermal / chemical corrosion), corneal ulcer, corneal opacity, corneal perforation, corneal scar, Stevens-Johnson syndrome, ocular pemphigoid, etc.), retinal diseases (e.g., retinitis pigmentosa, age-related macular degeneration, etc.), esophageal diseases (e.g., prevention of esophageal inflammation / stenosis after esophageal surgery (removal of esophageal cancer), etc.), skin diseases (e.g., skin damage ( Examples of diseases that may be included in the treatment include osteoporosis, ... The sheet-shaped cell culture of the present disclosure can be fragmented into an injectable size and injected into the area requiring treatment, which can provide a greater effect than injection of a single cell suspension (Wang et al., Cardiovasc Res. 2008;77(3):515-24). Therefore, the sheet-shaped cell culture of the present disclosure can also be used in this manner.

[0056] Another aspect of the present disclosure relates to a method of treating a disease in a subject in need thereof, comprising administering to said subject an effective amount of a graft produced by the method of the present disclosure. The disease to be treated is as described above.

[0057] In the present disclosure, the term "treatment" is intended to include all types of medically acceptable prophylactic and / or therapeutic interventions aimed at curing, temporarily ameliorating, or preventing a disease, etc. For example, the term "treatment" includes medically acceptable interventions for various purposes, including delaying or halting the progression of a disease associated with tissue abnormality, regressing or eliminating a lesion, preventing the onset of the disease or preventing recurrence, etc.

[0058] In the treatment method of the present disclosure, components that enhance the survival, engraftment and / or function of the graft, or other active ingredients that are useful for treating the target disease, can be used in combination with the graft of the present disclosure.

[0059] The treatment method of the present disclosure may further include a step of producing the graft of the present disclosure according to the production method of the present disclosure. The treatment method of the present disclosure may further include a step of collecting cells (e.g., skin cells, blood cells, etc., when iPS cells are used) or tissue that is a source of cells (e.g., skin tissue, blood, etc., when iPS cells are used) from a subject before the step of producing a graft. In one embodiment, the subject from which the cells or tissue that is a source of cells is collected is the same individual as the subject who receives the cell culture, composition, or graft, etc. In another embodiment, the subject from which the cells or tissue that is a source of cells is collected is a different individual of the same species as the subject who receives the cell culture, composition, or graft, etc. In another embodiment, the subject from which the cells or tissue that is a source of cells is collected is a different individual of the same species as the subject who receives the graft, etc.

[0060] In the present disclosure, an effective amount is, for example, an amount capable of suppressing the onset or recurrence of a disease, alleviating symptoms, or delaying or halting progression (e.g., size, weight, number of sheets, etc. of the sheet-shaped cell culture), and preferably an amount capable of preventing the onset or recurrence of the disease, or curing the disease. In addition, an amount that does not cause adverse effects that exceed the benefits of administration is preferable. Such an amount can be appropriately determined, for example, by tests using experimental animals such as mice, rats, dogs, or pigs, or disease model animals, and such test methods are well known to those skilled in the art. In addition, the size of the tissue lesion to be treated can be an important indicator for determining the effective amount.

[0061] Examples of the administration method include intravenous administration, intramuscular administration, intraosseous administration, intrathecal administration, and direct application to tissue. The frequency of administration is typically once per treatment, but if the desired effect is not obtained, multiple administrations are also possible. When applied to tissue, the cell culture, composition, or sheet-shaped cell culture of the present invention may be fixed to the target tissue by a fastening means such as sutures or staples.

[0062] The present invention will be described in more detail below by giving specific embodiments of the present invention, but the present invention is not limited to these specific examples. EXAMPLES

[0063] Example 1. Correlation between albumin concentration and number of recovered viable cells Cells obtained from skeletal muscle tissue aseptically collected from the femur of an adult human were seeded in a culture flask and grown in MCDB131 medium containing 20% ​​FBS. The grown cells were detached from the culture flask with a proteolytic enzyme solution, collected, and concentrated by centrifugation to obtain a cell population containing skeletal myoblasts.

[0064] Thawing of the cryopreserved cells and recovery of viable cells were performed as follows. The cell population obtained above (1.0 × 10 7Four cryotubes containing 1.8 mL of frozen cells (1000 cells / ml) were placed in a water bath set at 37°C for 2-3 minutes to thaw the frozen cells. The thawed cell suspension was transferred from the 1.8 mL cryotube to a 225 mL conical tube. Next, 30 mL of DMEM containing 0%, 0.5%, 1.25%, and 2.5% by weight of human serum albumin (HSA) was added dropwise to each conical tube at a constant speed, and the tubes were centrifuged at 4°C and 240 x g for 7 minutes, after which the supernatant was discarded. 30 mL of buffer containing HSA at each concentration was added again, and the tubes were centrifuged at 4°C and 240 x g for 7 minutes, after which the supernatant was discarded, and 5 mL of buffer containing HSA at each concentration was added to obtain a cell suspension. A portion of the obtained cell suspension was withdrawn and mixed with trypan blue, followed by cell counting, and the number of viable cells recovered after thawing was counted from the cell count results.

[0065] The number of viable cells recovered at each concentration, with the number of viable cells recovered when diluted with 0% HSA-containing DMEM set at 1, is shown in Figure 1. The number of viable cells recovered increased with increasing human serum albumin concentration, reaching its highest value at concentrations of 2.5% or higher.

[0066] Example 2. Consideration of buffer components In order to examine the components of the dilution buffer during freezing and thawing, (i) inorganic salts, (ii) sugars, (iii) vitamins, and (iv) amino acids, which will be described later, were Buffer solutions 1 to 5 were prepared at 1 L each, with the ingredients blended as shown in Table 1. 55 mg of sodium pyruvate, 2.39 mg of sodium hypoxanthine, 0.042 mg of linoleic acid, 0.105 mg of α-lipoic acid, 8.1 mg of phenol red, 0.081 mg of putrescine 2HCL, and 0.365 mg of thymidine were added to all of buffer solutions 1 to 5. The same procedure as in Example 1 was carried out, except that buffer solutions 1 to 5 containing 2.5 wt % HSA were used instead of Hanks' balanced salt solution containing HSA at four different concentrations as the buffer solution in Example 1. [Table 1]

[0067] (i) Inorganic salts: Calcium chloride (anhydrous): 116.6 mg, copper(II) sulfate·5H2O: 0.0013 mg, iron(III) trinitrate·9H2O: 0.05 mg, iron(II) sulfate·7H2O: 0.417 mg, magnesium chloride: 28.64 mg, magnesium sulfate (anhydrous): 48.84 mg, sodium bicarbonate: 2438 mg, potassium chloride: 311.8 mg, sodium chloride: 6995.5 mg, disodium hydrogen phosphate: 71.02 mg, sodium hydrogen phosphate·H2O: 62.5, zinc sulfate·7H2O: 0.432 mg (ii) Sugars D-glucose: 3151mg (iii) Vitamins Biotin: 0.0035mg, Choline Chloride: 8.98mg, Calcium D-Pantothenate: 2.24mg, Folic Acid: 2.65mg, Niacinamide: 2.02mg, Pyridoxal·HCl, 2.013mg, Riboflavin: 0.219mg, Thiamine·HCl: 2.17mg, Vitamin B12: 0.68mg, i-Inositol: 12.6mg (iv) Amino acids Glycine: 18.75mg, L-alanine: 4.45mg, L-Arginine·HCl: 0.084mg, L-Asparagine·H2O: 7.5mg, L-Aspartic acid: 6.65mg, L-Cysteine·HCl·H2O: 17.56mg, L-Cystine·2HCl: 31.29mg, L-Glutamic acid: 7.35mg, L-Glutamine: 365mg, L-Histidine·HCl·H2O: 31.48mg, L-Isoleucine: 54.47mg g, L-Leucine: 59.05 mg, L-Lysine·HCl: 91.25 mg, L-Methionine: 17.24 mg, L-Phenylalanine: 35.48 mg, L-Proline: 17.25 mg, L-Serine: 26.25 mg, L-Threonine: 53.45 mg, L-Tryptophan: 9.02 mg, L-Tyrosine·2Na·2H2O: 55.79 mg, L-Valine: 52.85 mg

[0068] A portion of the cell suspension obtained by diluting with buffers 1 to 5 was taken, and a cell count was performed before and after mixing with trypan blue to determine the total number of cells recovered and the number of viable cells recovered. The survival rate and recovery rate were calculated using the following formula. Viability (%) = number of viable cells after thawing / total number of cells after thawing x 100 Recovery rate (%) = number of viable cells after thawing / number of viable cells before thawing x 100 A portion of the cell suspension was taken and reacted with anti-CD56 antibody, and the rate of CD56 positive cells relative to viable cells was measured using a flow cytometer.

[0069] It was found that the medium of Buffer 1, which is a combination of three types of buffer, namely, sugars, vitamins, and amino acids, is particularly preferable as a buffer for dilution during freezing and thawing. Therefore, it was found that the number of recovered viable cells, survival rate, recovery rate, and ratio of CD56 positive cells can be increased by adding sugars, vitamins, and amino acids to the albumin-containing buffer in addition to inorganic salts, which are the base of the buffer, and diluting the albumin-containing buffer using this.

Claims

1. A buffer solution containing 1.0% by weight or more of human serum albumin and DMEM, The buffer solution is used to dilute and wash a cell suspension containing frozen preserved cells including skeletal myoblasts and then resuspend the cell suspension by dropping the cell suspension at a constant speed.

2. 2. The buffer solution according to claim 1, wherein the concentration of human serum albumin is 2.5 to 20% by weight.

3. 3. The buffer solution according to claim 1 or 2, wherein the buffer solution comprises sugars, amino acids, and / or vitamins.

4. A kit comprising the buffer solution according to any one of claims 1 to 3.

5. A method for recovering viable cells from cryopreserved cells including skeletal myoblasts, comprising: a step of diluting and washing the cell suspension obtained by thawing the cryopreserved cells by dropping a buffer solution containing 1.0% by weight or more of human serum albumin and DMEM into the cell suspension at a constant rate; and resuspending the washed cells in said buffer. The method comprising:

6. A method for increasing one or more numbers / ratios selected from the group consisting of number of recovered viable cells, survival rate, and recovery rate of cryopreserved cells including skeletal myoblasts, comprising: a step of diluting and washing the cell suspension obtained by thawing the cryopreserved cells by dropping a buffer solution containing 1.0% by weight or more of human serum albumin and DMEM into the cell suspension at a constant rate; and resuspending the washed cells in said buffer. The method comprising:

7. The method described in claim 5 or 6, further increasing the ratio of CD56 positive cells.

8. A method according to any one of claims 5 to 7, wherein the concentration of human serum albumin is 2.5 to 20% by weight.

9. The method according to any one of claims 5 to 8, wherein the buffer comprises sugars, amino acids, and / or vitamins.

10. A method for producing a graft comprising the method according to any one of claims 5 to 9.

11. A method for increasing one or more numbers / ratios selected from the group consisting of number of recovered viable cells, survival rate, and recovery rate of cryopreserved cells including skeletal myoblasts, comprising: adding one or more components selected from the group consisting of sugars, vitamins, and amino acids to a buffer solution containing 1.0% by weight of human serum albumin and DMEM, and thawing the frozen preserved cells to obtain a cell suspension, and diluting and washing the cell suspension by dropping the component-added buffer solution into the cell suspension at a constant speed; and Resuspending the washed cells in the component loading buffer. The method comprising:

12. The method described in claim 11, further increasing the ratio of CD56 positive cells.

13. The method according to claim 11 or 12, wherein the concentration of human serum albumin is 2.5 to 20% by weight.

Citation Information

Patent Citations

  • three-dimensional tissue structure

    JP2007528755A

  • Mesenchymal stromal cell populations, and methods for isolating and using them.

    JP2011529706A

  • Method of producing sheet-like cell culture

    JP2014143971A

  • Laminated body of sheet-like cell culture having reinforcement portion and fibrin gel

    JP2016052272A

  • Production method for sheet-shaped cell culture

    WO2014185517A1